PHILADELPHIA — Lannett Co. has completed its acquisition of Silarx Pharmaceuticals Inc, , a manufacturer and marketer of liquid generic drug products.

The deal also includes a related real estate entity, Lannett said Tuesday. When it announced the agreement in mid-May, Lannett said that it would retain Silarx’s entire senior management team, and there would be no layoffs or facility closings .

“Having invested time and resources in evaluating a number of potential acquisitions, we are extremely pleased that Silarx is now part of our company.  Today, we are a larger, more diverse and more capable organization,” stated Arthur Bedrosian, chief executive officer of Lannett.  “The acquisition brings a high-quality, talented workforce that we intend to retain and an FDA-approved manufacturing facility into which we can quickly increase utilization.

“Silarx also adds an exciting pipeline that includes four Abbreviated New Drug Applications (ANDAs) with Paragraph 4 certification pending at the FDA and a number of complementary products,” Bedrosian added.

Silarx manufactures and markets liquid pharmaceuticals, including generic prescription and over-the-counter products. The company recently moved into a 110,000-square-foot facility in Carmel, N.Y.

According to Lannett, Silarx was the first company to secure U.S. approval for a generic version of Viiv Healthcare’s Epivir (lamivudine) 10mg/ml oral solution, an antiviral medication for HIV and hepatitis B. Silarx also is the only manufacturer of loratadine oral solution, equivalent to the active ingredient of OTC allergy medicine Claritin, with the FDA-approved indication of hives relief.

Other key products from Silarx include the antidepressants citalopram oral solution (equivalent to the active ingredient of Celexa) and fluoxetine oral solution (equivalent to the active ingredient of Prozac).